|
KMID : 0371420140870020061
|
|
Annals of Surgical Treatment and Research
2014 Volume.87 No. 2 p.61 ~ p.65
|
|
|
Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience
|
|
Karabulut Kagan
Ozbalci G. Selcuk
Kesicioglu Tugrul
Tarim Ismail Alper
Lap Gokhan
Polat Ayfer Kamali
Karabıcak Ilhan
Erzurumlu Kenan
|
|
|
Abstract
|
|
|
Purpose: The aim of this study was to evaluate long-term outcome of the intraoperative and perioperative albendazole (ALB) treatment on the recurrence and/or secondary hydatidosis.
Methods: One hundred and one patients with hepatic hydatidosis were treated intraoperatively and perioperatively with ALB, in addition to surgery. Perioperative ALB treatment was given in a dose of 12-15 mg/kg/day. The ALB treatment was started 13.27 ± 14.34 days before the surgery, and it was continued for 4.39 ± 3.11 months postoperatively. A total of 1.7 μg/mL of ALB solution was used as a protoscolidal agent. The follow-up period was 134.55 ± 51.56 months.
Results: Four patients died, with only one death was secondary to hydatid disease (cerebral eccinococcus). There was only one recurrence (1%) of hepatic hydatidosis. Early and late morbidity rates were 8.91% and 7.92%, respectively.
Conclusion: Our results suggest that intraoperative and perioperative ALB is effective for the prevention of hepatic hydatidosis recurrence and/or secondary hydatidosis.
|
|
|
KEYWORD
|
|
|
Albendazole, Hepatic echinococcosis, Recurrence
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|